The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPS
Active, not recruiting
- Conditions
- Secondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondary
- Registration Number
- EUCTR2007-006645-41-NL
- Lead Sponsor
- Sint Lucas Andreas Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Hemodialysis patients of 18 years and older.
- Secondary hyperparathyroidism.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Severe hypercalcemia (Ca2+ > 2,65 mmol/L)
Severe hepatic dysfunction
Overdosage of digoxin
Hypersensitivity to vitamin D or overdosage of vitmain D
Parathyroidectomia in the past
< 18 years of age
Pregnancy
Mentall illness
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method